156682-52-9

Basic information

• Product Name: 1,4-DIBROMO-2,3-DIFLUOROBENZENE
• Synonyms: 1,4-Dibromo-2,3-difluorobenzene 97%;Benzene,1,4-dibroMo-2,3-difluoro-
• CAS NO: 156682-52-9
• Molecular Formula: C₆H₂Br₂F₂
• Molecular Weight: 271.9
• EINECS: 1592732-453-0
• Mol File: 156682-52-9.mol

Chemical Properties

• Boiling Point: 212℃
• Flash Point: 82℃
• Appearance: /
• Density: 2.087
• Vapor Pressure: 0.259mmHg at 25°C
• Refractive Index: 1.5620-1.5660
• Storage Temp.: 0-10°C
• CAS DataBase Reference: 1,4-DIBROMO-2,3-DIFLUOROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DIBROMO-2,3-DIFLUOROBENZENE(156682-52-9)
• EPA Substance Registry System: 1,4-DIBROMO-2,3-DIFLUOROBENZENE(156682-52-9)

Safety Data

• Hazardous Substances Data: 156682-52-9(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Industry:
1,4-Dibromo-2,3-difluorobenzene is used as a key intermediate in the synthesis of various biologically active compounds. One of its primary applications is in the preparation of non-nucleoside reverse transcriptase inhibitors (NNRTIs), which are essential in the treatment of retroviral infections, particularly human immunodeficiency virus (HIV).
2. Used in Organic Photovoltaics:
1,4-Dibromo-2,3-difluorobenzene is also utilized in the synthesis of conjugated polymers, which are crucial components in the development of organic photovoltaic (OPV) devices. These polymers play a significant role in the light absorption and charge transport processes within the OPV system, contributing to the overall efficiency and performance of the solar cells.

InChI:InChI=1/C6H2Br2F2/c7-3-1-2-4(8)6(10)5(3)9/h1-2H

Upstream product

• 75-61-6 dibromodifluoromethane 
• 38573-88-5 1-bromo-2,3-difluorobenzene 
• 367-11-3 ortho-difluorobenzene 
• 867366-94-7 (2,3-difluoro-1,4-phenylene)bis(trimethylsilane) 

Downstream Products

• 1309366-56-0 4,4'-(2,3-difluoro-1,4-phenylene)dipyridine 
• 1456901-31-7 6,7-difluoro-2,3-bis(3-(octyloxy)phenyl)-5,8-di(thiophen-2-yl)quinoxaline 
• 1416056-61-5 5,8-bis(5-bromothiophen-2-yl)-6,7-difluoro-2,3-bis(3-(octyloxy)phenyl)quinoxaline 
• 1415801-13-6 5,8-dibromo-6,7-difuoro-2,3-bis(3-(octyloxy)phenyl)quinoxaline 
• 1450590-76-7 4,7-di(4-hexyl-5-bromothiophen-2-yl)-5,6-difluorine-2,1,3-benzothiadiazole 
• 1416047-42-1 5,8-dibromo-6,7-difluoro-2,3-bis(3-hexyloxyphenyl)quinoxaline 
• 1416047-43-2 C₄₀H₄₀F₂N₂O₂S₂ 
• 1416047-44-3 5,8-bis(5-bromothiophen-2-yl)-6,7-difluoro-2,3-bis(3-(hexyloxy)phenyl)quinoxaline 
• 1612223-70-7 1-(4-bromo-2,3-difluorophenyl)-3-methylbutan-1-ol 
• 1612223-72-9 1-((3S)-1-(1-(4-bromo-2,3-difluorophenyl)-3-methylbutyl)piperidin-3-yl)-5-methylpyrimidine-2,4(1H,3H)-dione 
• 1612223-71-8 1-(4-bromo-2,3-difluorophenyl)-3-methylbutyl methanesulfonate 
• 1360726-52-8 2,5-dibromo-3,4-difluoro-1-nitrobenzene 

Relevant articles and documents

NOVEL ANTIBIOTICS AND METHODS OF USING SAME

The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subjec

Syntheses and photovoltaic properties of 6-(2-thienyl)-4H-thieno[3,2-b]indole based conjugated polymers containing fluorinated benzothiadiazole

In this report, a series of copolymers based on 6-(2-thienyl)-4H-thieno[3,2-b]indole (TTI) as an electron-rich unit and fluorinated DTBT as an electron-deficient unit were synthesized, namely PTTIF1 and PTTIF2, and applied to photovoltaic devices. TTI unit was coupled with fluorinated DTBT to utilize the merit of introduction of fluorine atom leading to the lowering of the HOMO energy level while keeping high planarity of the conjugated backbone. The synthesized copolymers show a noticeable change in HOMO energy levels as compared with non-fluorinated polymer (PTTIDTBT-h). Optimized photovoltaic devices of PTTIF2 exhibited power conversion efficiency of 4.36% with decent JSC and FF values, which can be explained by the higher charge transporting ability of PTTIF2 with preferable face-on crystallite population than PTTIF1 in grazing incident wide-angle X-ray scattering (GIWAXS).

Molecular-level architectural design using benzothiadiazole-based polymers for photovoltaic applications

A series of low band gap, planar conjugated polymers, P1 (PFDTBT), P2 (PFDTDFBT) and P3 (PFDTTBT), based on fluorene and benzothiadiazole, was synthesized. The effect of fluorine substitution and fused aromatic spacers on the optoelectronic and photovoltaic performance was studied. The polymer, derived from dithienylated benzothiodiazole and fluorene, P1, exhibited a highest occupied molecular orbital (HOMO) energy level at -5.48 eV. Density functional theory (DFT) studies as well as experimental measurements suggested that upon substitution of the acceptor with fluorine, both the HOMO and lowest unoccupied molecular orbital (LUMO) energy levels of the resulting polymer, P2, were lowered, leading to a higher open circuit voltage and short circuit current with an overall improvement of more than 110% for the photovoltaic devices. Moreover, a decrease in the torsion angle between the units was also observed for the fluorinated polymer P2 due to the enhanced electrostatic interaction between the fluorine substituents and sulfur atoms, leading to a high hole mobility. The use of a fused π-bridge in polymer P3 for the enhancement of the planarity as compared to the P1 backbone was also studied. This enhanced planarity led to the highest observed mobility among the reported three polymers as well as to an improvement in the device efficiency by more than 40% for P3.

Quinoxaline-based polymer dots with ultrabright red to near-infrared fluorescence for in vivo biological imaging

This article describes the design and synthesis of quinoxaline-based semiconducting polymer dots (Pdots) that exhibit near-infrared fluorescence, ultrahigh brightness, large Stokes shifts, and excellent cellular targeting capability. We also introduced fluorine atoms and long alkyl chains into polymer backbones and systematically investigated their effect on the fluorescence quantum yields of Pdots. These new series of quinoxaline-based Pdots have a fluorescence quantum yield as high as 47% with a Stokes shift larger than 150 nm. Single-particle analysis reveals that the average per-particle brightness of the Pdots is at least 6 times higher than that of the commercially available quantum dots. We further demonstrated the use of this new class of quinoxaline-based Pdots for effective and specific cellular and subcellular labeling without any noticeable nonspecific binding. Moreover, the cytotoxicity of Pdots were evaluated on HeLa cells and zebrafish embryos to demonstrate their great biocompatibility. By taking advantage of their extreme brightness and minimal cytotoxicity, we performed, for the first time, in vivo microangiography imaging on living zebrafish embryos using Pdots. These quinoxaline-based NIR-fluorescent Pdots are anticipated to find broad use in a variety of in vitro and in vivo biological research.

D-A copolymers based on 5,6-difluorobenzotriazole and oligothiophenes: Synthesis, field effect transistors, and polymer solar cells

Two new 5,6-difluorobenzotriazole (FBTA)-oligothiophene copolymers PFBTA-3T and PFBTA-4T, comprising terthiophene (3T) and quaterthiophene (4T) on the backbone, respectively, were successfully synthesized. A new route to synthesize FBTA monomer was established. Polymers PFBTA-3T and PFBTA-4T exhibited good solubility in common organic solvents and good thermal stability. In comparison to poly (3-hexylthiophene), the incorporations of the FBTA as in PFBTA-3T and PFBTA-4T could result in smaller band gaps around 1.83 eV for the two copolymers. The HOMO levels of PFBTA-3T and PFBTA-4T were -5.49 and -5.31 eV, respectively, while their LUMO levels were -3.65 and -3.90 eV, respectively. In field-effect transistors fabricated without high temperature thermal annealing, PFBTA-3T and PFBTA-4T could display hole mobilities of 1.68 × 10 -3 and 1.31 × 10-2 cm2 V-1 s-1, respectively. The mobility for PFBTA-4T is the highest among the reported FBTA-based polymers, suggesting that FBTA is a promising heterocycle to construct polymers with high mobility. Polymer solar cells were also fabricated with PFBTA-3T and PFBTA-4T as the donor and PC61BM as the acceptor. With copolymer: PC61BM = 1:1.5 as the active layers, polymer solar cells showed power conversion efficiencies of 3.0% and 2.51% for PFBTA-3T and PFBTA-4T, respectively.

Soft secondary building unit: Dynamic bond rearrangement on multinuclear core of porous coordination polymers in gas media

A new synthetic approach to prepare flexible porous coordination polymers (PCPs) by the use of soft secondary building units (SBUs) which can undergo multiple reversible metal-ligand bonds breaking is reported. We have prepared a zinc paddle-wheel-based t

Increased open circuit voltage in fluorinated benzothiadiazole-based alternating conjugated polymers

Small band-gap conjugated polymers based on monofluoro- and difluoro-substituted benzothiadiazole were developed. Highly efficient polymer solar cells (PCE as high as 5.40%) could be achieved for devices made from these polymers.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.